Did you mean sars amino?
Displaying drugs 176 - 200 of 4629 in total
Chloroprocaine
Chloroprocaine is an ester local anesthetic commonly available in its salt form, chloroprocaine hydrochloride. Similar to other local anesthetics, it increases the threshold for electrical excitation in nerves by slowing the propagation of the nerve impulse and reducing the rate of rise of the action potential. The pharmacological profile of...
Approved
Investigational
Vilazodone
Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors[Label,A177622]. Vilazodone may also be associated with less sexual dysfunction and weight gain . Vilazodone was given FDA approval on January 21, 2011[L6046,A177622].
Approved
Meperidine
A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.
Approved
Quinine
An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in...
Approved
Oxycodone
Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The first oxycodone...
Approved
Illicit
Investigational
Dextropropoxyphene
Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe...
Approved
Illicit
Investigational
Withdrawn
Nalbuphine
A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States.
Approved
Quinidine
Quinidine is a D-isomer of quinine present in the bark of the Cinchona tree and similar plant species. This alkaloid was first described in 1848 and has a long history as an antiarrhythmic medication.[A38016,A250050] Quinidine is considered the first antiarrhythmic drug (class Ia) and is moderately efficacious in the acute...
Approved
Investigational
Paromomycin
An oligosaccharide antibiotic produced by various streptomyces. [PubChem]
Approved
Investigational
Ribostamycin
Ribostamycin is an aminoglycoside antibiotic isolated from Streptomyces ribosidificus listed as one of the World Health Organization's critically important antimicrobials.
Approved
Experimental
Oxeladin
Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.
Approved
Withdrawn
Celiprolol
Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris. It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist. In 2010 a clinical trial has suggested a use for this medication in the prevention of...
Approved
Investigational
Vildagliptin
Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired. By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP),...
Approved
Investigational
Niraparib
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or...
Approved
Investigational
Manidipine
Manidipine (INN) is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive. It is selective for vasculature and does not produce effects on the heart at clinically relevant dosages.
Approved
Investigational
Aminocaproic acid
An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
Approved
Investigational
Indacaterol
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as...
Approved
Fosaprepitant
Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.
Approved
Acrivastine
Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema, bronchoconstriction, and tachycardia.
Acrivastine is...
Approved
Padimate O
Padimate O is an active sunscreen agent in cosmetics and over-the-counter sunscreen drug products in concentrations up to 8%, as regulated by the FDA . It is a structurally-related compound to DB02362 that absorbs UV-B rays to prevent photodamage. It penetrates human skin, and is shown to induce non-ligatable strand...
Approved
Nefopam
Nefopam is under investigation for the prevention of Cholecystitis and Post Anaesthetic Shivering. Nefopam has been investigated for the prevention of Kidney Transplantation.
Approved
Investigational
Relebactam
Relebactam is a diazabicyclooctane beta-lactamase inhibitor, similar in structure to avibactam.[A181195,A181207] It includes a piperidine ring which reduces export from bacterial cells by producing a positive charge. It is currently available in a combination product which includes imipenem and cilastatin to treat complicated urinary tract infections (UTIs), pyelonephritis, and complicated...
Approved
Investigational
Pramiracetam
Pramiracetam has been previously approved in some eastern European countries under the brand names Pramistar, Neupramir, and Remen. It was also previously approved in the United States with orphan drug designation . Pramiracetam has been studied for the use in Alzheimer's disease and as an adjunct treatment to restore cognitive...
Approved
Dacomitinib
Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on...
Approved
Investigational
Displaying drugs 176 - 200 of 4629 in total